Precipio (NASDAQ:PRPO) Posts Quarterly Earnings Results

Precipio (NASDAQ:PRPO) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.12) EPS for the quarter, Zacks reports. The firm had revenue of $7.02 million during the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.73%.

Precipio Trading Up 1.2%

Precipio stock traded up $0.29 during midday trading on Friday, hitting $23.50. 75,806 shares of the stock were exchanged, compared to its average volume of 42,911. The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05. The stock’s 50-day simple moving average is $23.42 and its 200 day simple moving average is $25.03. Precipio has a fifty-two week low of $13.80 and a fifty-two week high of $33.63. The stock has a market capitalization of $42.06 million, a price-to-earnings ratio of -50.00 and a beta of 1.30.

Hedge Funds Weigh In On Precipio

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Precipio in the third quarter valued at approximately $194,000. Institutional investors and hedge funds own 10.45% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on PRPO. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Friday, July 17th. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Precipio currently has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.